Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial

Abstract

Teliso-V was associated with durable responses in c-Met protein-overexpressing nonsquamous <i>EGFR</i>-wildtype NSCLC, especially in those with high c-Met. AEs were generally manageable.